申请人:Mitsubishi Tanabe Pharma Corporation
公开号:EP2532658A1
公开(公告)日:2012-12-12
The present invention provides a novel therapeutic drug for cerebral infarction, which contains a piperazine compound as an active ingredient.
The compound of the present invention can be provided as a novel therapeutic drug for cerebral infarction having an effect of suppressing brain injury volume or improving neurological deficit, since it suppresses production of plural inflammatory cytokines and chemokines present in the brain such as TNF-α, IL-1β, IL-6 and MCP-1 and the like.
本发明提供了一种新型脑梗塞治疗药物,其有效成分为哌嗪化合物。
本发明的化合物可以作为一种新型脑梗塞治疗药物,具有抑制脑损伤体积或改善神经功能缺损的作用,因为它可以抑制脑内存在的多种炎性细胞因子和趋化因子,如 TNF-α、IL-1β、IL-6 和 MCP-1 等的产生。